Special Drug Use-results Surveillance for long term administration of XEPLION (Paliperidone Palmitate 1 month formulation), 25mg/ 50mg/ 75mg/ 100mg/ 150mg syringe

Special Drug Use-results Surveillance for long term administration of XEPLION (Paliperidone Palmitate 1 month formulation), 25mg/ 50mg/ 75mg/ 100mg/ 150mg syringe - Special Drug Use-results Surveillance for long term administration of XEPLION (Paliperidone Palmitate 1 month formulation), 25mg/ 50mg/ 75mg/ 100mg/ 150mg syringe

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018665

Enrollment

1050

Registered

2015-08-13

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Schizophrenia patients who are treated with XEPLION for the first time

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

Measure	Time frame
Safety(Adverse Drug Reaction) Effectiveness(Clinical Global Impression-Schizophrenina Scale:CGI-SCH)	—

Secondary

Measure	Time frame
Effectiveness(SOFAS) Effectiveness(MSQ)	—

Countries

Japan

Contacts

Public ContactKeiko Imai

Janssen Pharmaceutical K.K. Safety Risk Management Depertment

kimai4@its.jnj.com03-4411-5752

Outcome results